Product nameAnti-PON1 antibody [17A12]
See all PON1 primary antibodies
DescriptionMouse monoclonal [17A12] to PON1
Tested applicationsSuitable for: ChIP, ICC/IF, IHC-P, IHC-FoFr, ELISA, WB, Flow Cytmore details
Species reactivityReacts with: Mouse, Rat, Hamster, Human, Rhesus monkey
Predicted to work with: Rabbit
His tagged recombinant Human PON1 protein purified E.coli.
- HeLa, HepG2 cell lysates, mouse liver tissue lysate.
This product was changed from ascites to tissue culture supernatant on 18th September 2017. Lot numbers higher than GR202765 will be from tissue culture supernatant. Please note that the dilutions may need to be adjusted accordingly.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.03% Sodium azide
Constituents: HEPES, 50% Glycerol, 0.87% Sodium chloride, 0.01% BSA
PurityTissue culture supernatant
Light chain typekappa
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
Our Abpromise guarantee covers the use of ab24261 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ChIP||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
|IHC-P||Use at an assay dependent concentration.|
|IHC-FoFr||Use at an assay dependent concentration.|
|ELISA||Use at an assay dependent concentration.|
|WB||Use a concentration of 4 mg/ml. Predicted molecular weight: 40 kDa.|
|Flow Cyt||Use at an assay dependent concentration.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionHydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation.
Tissue specificityPlasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas.
Involvement in diseaseGenetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5) [MIM:612633]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients.
Sequence similaritiesBelongs to the paraoxonase family.
The signal sequence is not cleaved.
Present in two forms, form B contains a disulfide bond, form A does not.
Cellular localizationSecreted > extracellular space.
- Information by UniProt
- A esterase 1 antibody
- A-esterase 1 antibody
- Aromatic esterase 1 antibody
All lanes : Anti-PON1 antibody [17A12] (ab24261) at 1/500 dilution
Lane 1 : HeLa cell lysates.
Lane 2 : HepG2 cell lysates.
Predicted band size: 40 kDa
ab24261 (1µg/ml) staining PON1 in human liver using an automated system (DAKO Autostainer Plus). Using this protocol there is strong cytoplasmic staining of hepatocytes.
Sections were rehydrated and antigen retrieved with the Dako 3 in 1 AR buffer citrate pH 6.0 in a DAKO PT link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 mins. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 min and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with Diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that, for manual staining, optimization of primary antibody concentration and incubation time is recommended. Signal amplification may be required.
Overlay histogram showing HepG2 cells stained with ab24261 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab24261, 1µg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 100% methanol (5 min)/permeabilized in 0.1% PBS-Tween used under the same conditions.
ICC/IF image of ab24261 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab24261, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Cao J et al. Protein markers of dysfunctional HDL in scavenger receptor class B type I deficient mice. J Transl Med 16:155 (2018). WB ; Mouse . Read more (PubMed: 29879989) »
- Cho KH et al. Consumption of Cuban Policosanol Improves Blood Pressure and Lipid Profile via Enhancement of HDL Functionality in Healthy Women Subjects: Randomized, Double-Blinded, and Placebo-Controlled Study. Oxid Med Cell Longev 2018:4809525 (2018). Read more (PubMed: 29854085) »